Literature DB >> 17031523

Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers.

Yong Wang1, Shizhong Wang, Yongyi Bao, Cheng Ni, Naifu Guan, Jianzhong Zhao, Leif G Salford, Bengt Widegren, Xiaolong Fan.   

Abstract

Adenoviral vector mediated gene delivery has been applied in clinical trials and mechanistic studies to explore new treatment approaches for lung cancers. The expression of coxsackievirus adenovirus receptor (CAR), the primary receptor for the most commonly used adenovirus serotype 5 (Ad5)-based vectors, predominantly determines the permissiveness of lung cancer cells. CAR expression is also suggested to modulate tumor cell proliferation capacity. Here, we studied CAR expression in archival lung cancer specimens by using well-characterized CAR 72 antibodies. High levels of CAR expression were observed in most of the 32 cases of squamous cell carcinoma lung cancers and in all the five cases of small cell lung cancers investigated. In contrast, high levels of CAR expression were detected only in 6 of 22 adenocarcinoma lung cancers. The relative levels of CAR expression did not correlate with the pathologic grade in lung cancers, and was thus inconsistent with a role of modulating cancer cell proliferation. Of note, CAR expression was not detected in non-malignant alveolar cells. Our data suggest a preferred utility of Ad5 vector mediated gene delivery to squamous cell carcinoma lung cancers, small cell lung cancers, but not to the majority of adenocarcinoma lung cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031523     DOI: 10.1007/s10735-006-9055-4

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  32 in total

1.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  Identification of bronchioalveolar stem cells in normal lung and lung cancer.

Authors:  Carla F Bender Kim; Erica L Jackson; Amber E Woolfenden; Sharon Lawrence; Imran Babar; Sinae Vogel; Denise Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

3.  Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.

Authors:  J A Roth; S G Swisher; J A Merritt; D D Lawrence; B L Kemp; C H Carrasco; A K El-Naggar; F V Fossella; B S Glisson; W K Hong; F R Khurl; J M Kurie; J C Nesbitt; K Pisters; J B Putnam; D S Schrump; D M Shin; G L Walsh
Journal:  Semin Oncol       Date:  1998-06       Impact factor: 4.929

4.  Apical localization of the coxsackie-adenovirus receptor by glycosyl-phosphatidylinositol modification is sufficient for adenovirus-mediated gene transfer through the apical surface of human airway epithelia.

Authors:  R W Walters; W van't Hof; S M Yi; M K Schroth; J Zabner; R G Crystal; M J Welsh
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.

Authors:  J T Douglas; M Kim; L A Sumerel; D E Carey; D T Curiel
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

6.  The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure.

Authors:  T Okegawa; R C Pong; Y Li; J M Bergelson; A I Sagalowsky; J T Hsieh
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

7.  Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors.

Authors:  R K Batra; J C Olsen; R J Pickles; D K Hoganson; R C Boucher
Journal:  Am J Respir Cell Mol Biol       Date:  1998-03       Impact factor: 6.914

8.  Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

Authors:  John Nemunaitis; Daniel Sterman; David Jablons; John W Smith; Bernard Fox; Phil Maples; Scott Hamilton; Flavia Borellini; Andy Lin; Sayeh Morali; Kristen Hege
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

9.  The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis.

Authors:  Elisabeth Raschperger; Johan Thyberg; Sven Pettersson; Lennart Philipson; Jonas Fuxe; Ralf F Pettersson
Journal:  Exp Cell Res       Date:  2006-03-15       Impact factor: 3.905

10.  Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts.

Authors:  Min Qin; Shuang Chen; Tina Yu; Brian Escuadro; Sherven Sharma; Raj K Batra
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  13 in total

1.  Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients.

Authors:  Xue Yang; Shuangshuang Li; Huiju Wang; Wanyuan Chen; Xiaozhou Mou; Shibing Wang
Journal:  Oncol Lett       Date:  2018-12-24       Impact factor: 2.967

2.  Novel splice variant CAR 4/6 of the coxsackie adenovirus receptor is differentially expressed in cervical carcinogenesis.

Authors:  Marit Dietel; Norman Häfner; Lars Jansen; Matthias Dürst; Ingo B Runnebaum
Journal:  J Mol Med (Berl)       Date:  2011-03-23       Impact factor: 4.599

3.  Expression of the coxsackie and adenovirus receptor in human lung cancers.

Authors:  Zhaoli Chen; Qian Wang; Jingran Sun; Ankang Gu; Min Jin; Zhiqiang Shen; Zhigang Qiu; Jingfeng Wang; Xinwei Wang; Zhongli Zhan; Jun-Wen Li
Journal:  Tumour Biol       Date:  2013-01-11

4.  Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis.

Authors:  M Reeh; M Bockhorn; D Görgens; M Vieth; T Hoffmann; R Simon; J R Izbicki; G Sauter; U Schumacher; M Anders
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

5.  Two types of functionally distinct fiber containing structural protein complexes are produced during infection of adenovirus serotype 5.

Authors:  Bo Zhang; Yuhua Yan; Jie Jin; Hongyu Lin; Zongyi Li; Xiaoyan Zhang; Jin Liu; Chao Xi; Andre Lieber; Xiaolong Fan; Liang Ran
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

6.  Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population.

Authors:  Ying-Yu Ma; Xiao-Jun Wang; Yong Han; Gang Li; Hui-Ju Wang; Shi-Bing Wang; Xiao-Yi Chen; Fan-Long Liu; Xiang-Lei He; Xiang-Min Tong; Xiao-Zhou Mou
Journal:  Mol Med Rep       Date:  2016-07-21       Impact factor: 2.952

Review 7.  Novel oncolytic viral therapies in patients with thoracic malignancies.

Authors:  Zeeshan Ahmad; Robert A Kratzke
Journal:  Oncolytic Virother       Date:  2016-12-21

8.  Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence.

Authors:  Johan Rebetz; Manli Na; Changqing Su; Bo Holmqvist; Anna Edqvist; Cecilia Nyberg; Bengt Widegren; Leif G Salford; Hans Olov Sjögren; Niklas Arnberg; Qijun Qian; Xiaolong Fan
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

Review 9.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

10.  Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications.

Authors:  Costas T Giaginis; Apostolos C Zarros; Maria A Papaefthymiou; Aikaterini E Papadopouli; Ioannis K Sfiniadakis; Stamatios E Theocharis
Journal:  World J Surg Oncol       Date:  2008-06-17       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.